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Background: The first aim of the study was to investigate the accuracy and intra-laboratory variation of serum
creatinine measurements in clinical laboratories in Flanders. The second purpose was to check the effect of this
variation in serum creatinine concentration results on the calculated estimated glomerular filtration rate (eGFR) and
the impact on classification of patients into a chronic kidney disease (CKD) stage.
Methods: 26 routine instruments were included, representing 13 different types of analyzers from 6 manufacturers
and covering all current methodologies (Jaffe, compensated Jaffe, enzymatic liquid and dry chemistry methods).
Target values of five serum pools (creatinine concentrations ranging from 35 to 934 μmol/L) were assigned by the
gold standard method (ID-GC/MS).
Results: Intra-run CV (%) (n = 5) and bias (%) from the target values were higher for low creatinine concentrations.
Especially Jaffe and enzymatic dry chemistry methods showed a higher error. The calculated eGFR values
corresponding with the reported creatinine concentration ranges resulted in a different CKD classification in 47%
of cases.
Conclusions: Although most creatinine assays claim to be traceable to the gold standard (ID-GC/MS), large
inter-assay differences still exist. The inaccuracy in the lower concentration range is of particular concern and may
lead to clinical misinterpretation when the creatinine-based eGFR of the patient is used for CKD staging. Further
research to improve harmonization between methods is required.
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The calculation of the estimated glomerular filtration
rate (eGFR) using mathematical formulas has been
encouraged as a simple, rapid and reliable way of asses-
sing kidney function. A problem related to the use of
creatinine-based eGFR formulas is the existing diversity
of methods to determine serum creatinine (Scr). Small
analytic changes in Scr can create major shifts in the
distributions of eGFR, which then cause large differences
in the eGFR-based chronic kidney disease (CKD) classifi-
cation of patients [1]. So it is clear that control of la-
boratory analysis of Scr and worldwide standardized
Scr measurements are necessary. According to the
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unless otherwise stated.recommendations, manufactures already made efforts
to standardize their Scr measurements to have calibra-
tion traceable to the isotope dilution gas chromatog-
raphy/mass spectrometry (ID-GC/MS) gold standard
method. However calibration traceability does not ad-
dress non-specificity which remains of concern.
In the Jaffe reaction creatinine forms a coloured prod-
uct after addition of alkaline picrate. However, proteins,
glucose and substances with a ketone group are known
to interfere [2]. Many manufacturers tried to improve
the performance characteristics of the Jaffe reaction by
compensating for these interferences (eg. rate blanking
and subtraction of a fixed factor to compensate for non-
specific reactions). Since 1970 enzymatic assays were
developed to improve creatinine specificity. These en-
zymatic methods have generally fewer interferences thanhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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staging of CKD [3]. The higher cost of the enzymatic Scr
assay is the main reason why the use of Jaffe or compen-
sated Jaffe assays is still in practice [4]. Recently Piéroni
et al. demonstrated substantial improvement in the cali-
bration, traceability and precision of the enzymatic
methods, reaching the NKDEP recommendations [5].
The importance of standardized creatinine measure-
ments to calculate eGFR in a correct way has also led to
the development of improved creatinine-based eGFR
equations. Two of the most popular eGFR formulas, the
original pediatric Schwartz equation [6] and the original
MDRD (Modification of Diet in Renal Disease) [7] equa-
tion, were derived using Scr levels measured by the
kinetic Jaffe method. This method is known to overesti-
mate ID-GC/MS-traceable Scr up to 20%. After the
widespread standardization of creatinine measurement
methods both equations were re-expressed for ID-GC/
MS standardized (compensated Jaffe or enzymatic) Scr
[8-10]. Also the popular CKD-EPI (Chronic Kidney Dis-
ease Epidemiology Collaboration) equation [11] was de-
veloped to be used only with ID-GC/MS standardized
Scr. Unfortunately, the restricted use of these formulas
for specific creatinine methods has not been an overrid-
ing concern in some studies.
Our study was performed after the widespread
standardization of creatinine measurement methods
and reports on the status of standardization in clinical
laboratories in Belgium – Flanders. The first aim of the
present study was to investigate the intra-run variation
and accuracy (bias) of commonly used Scr assays in
Flanders. It was our goal to include all current method-
ologies including Jaffe, compensated Jaffe and enzym-
atic assays (dry or liquid chemistry). Our interest was
to study how results can vary if patients are followed in
different laboratories that work with various assays or
instruments eg. in the lab of the general practitioner or
in the lab of the specialized doctor in the hospital. The
second purpose was to investigate the effect of the
variation in Scr determination on eGFR values and on
the CKD classification for some specific patient cases.
Five fresh frozen serum pools were prepared in a large
concentration range (35 to 934 μmol/L) by minimal
processing. Therefore the properties of the serum pools
are comparable with authentic clinical samples (com-
mutable). This is a major advantage over the non-
commutable control materials (eg. lyophilized) typically
used in (inter)national proficiency schemes. In contrast
to the study of Piéroni et al. [5], we specified that the
routine settings were used instead of performing cali-
bration just before the run of the study samples. The
participants were also asked to report the results like
they usually do. This approach mirrors the best the ac-
tual situation.Methods
Preparation of serum pools
The creatinine samples of different concentrations were
prepared in AZ Groeninge Hospital Kortrijk, Belgium by
pooling fresh leftovers of patient serum samples. The
samples of coagulated blood were centrifuged (10 min at
3000 rpm) immediately after arrival in the laboratory.
The creatinine concentration was determined enzymati-
cally on a Cobas 6000 (Roche) and the samples were
stored at 4°C (max 3 days). According to the creatinine
concentration the serum was added to a specific frozen
pool (n = 5) and allowed to freeze at −20°C on top of the
already frozen material. All pools were prepared within
one week. Once the needed volume was reached, the
pools were thawed at room temperature and homoge-
nized (30 min, roller mixer). Afterwards the thawed
pools were centrifuged (10 min, 3000 rpm). No pellet
was visible.
The combined serum samples were tested for viral ser-
ology and found negative for hepatitis B surface antigen,
hepatitis C virus, human immunodeficiency virus and
syphilis. In all pools bilirubin was <53 μmol/L, triglycer-
ides <1.92 mmol/L and no hemolysis was observed [12].
One mL aliquots of the homogenized pools were frozen
at −80°C until shipping on dry ice to the reference la-
boratory (ID-GC/MS) and to the 22 participating clinical
laboratories.
The study was approved by the local Ethical Commit-
tee of the AZ Groeninge Hospital Kortrijk, Belgium (ref-
erence number B39620140695). Since the pools were
prepared using remains of patient serum samples that
were anonymized, it was not necessary to obtain written
informed consent.Target assignment of serum pools
Because the ID-GC/MS method is believed to be with-
out interference of other substances it is considered
the best method for determining creatinine concentra-
tions. The target values were assigned by an ID-GC/MS
reference method approved by the international Joint
Committee on Traceability in Laboratory Medicine
(JCTLM) (Department of Analytical Chemistry of Prof.
Dr. Thienpont at the University of Ghent, Belgium)
[13,14]. Since it is a highly laborious and costly method,
only a few highly specialized laboratories worldwide are
offering this method. The measurement protocol consisted
of analysis of each sample in triplicate on 3 independent
occasions (separate sampling, sample preparation, inde-
pendent calibration and mass-spectrometry measure-
ment). Calibration mixtures were always prepared from
three independently prepared working solutions. The
expanded uncertainty (k = 2) for that measurement
protocol was estimated to be 2.8%.
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We set up an experiment to test whether the freeze-
thaw cycle used to prepare the serum pools had altered
the properties of creatinine and thus commutability.
Over a period of three days, the same volume of serum
obtained from patient samples (n = 23) was added to a
liquid pool that was saved in the fridge at 4°C and separ-
ately to a pool that was kept frozen at −20°C. After-
wards, 30 aliquots were taken from the liquid pool and
from the defrosted pool respectively and analyzed for
Scr in one run on the Cobas 6000 (Roche). The sample
size of n = 30 for this experiment was obtained from
Pass12, NCSS statistical software (Kaysville, Utah, USA),
based on the following: an equivalence test of means
using two one-sided tests on data from a parallel-group
design with sample sizes of 30 in the liquid pool and 30
in the defrosted pool achieves 90% power at a 5% signifi-
cance level when the true difference between the means
is 1.24 μmol/L (the maximum allowed difference that
is considered equivalent), the standard deviation is
1.00 μmol/L and the equivalence limits are −2.00 and
2.00 μmol/L.
Serum creatinine measurements
The pools were shipped on dry ice to the 22 participat-
ing labs (14 hospital laboratories and 8 non-hospital la-
boratories) and were measured within one month after
arrival. In the meantime, the pools were kept frozen inTable 1 Characteristics of methods used by the participants
Instrument
Manufacturer Analyzer Rea
Beckman Coulter Inc, Brea, CA, USA LX 20 Clinical System
(Synchron)
CRE
UniCel DxC 800 Synchron
Clinical System
CRE
Roche Diagnostics, Mannheim,
Germany
Modular P CRE
com
Integra 400 plus Cre
CRE
Integra 800 Cre
CRE
Cobas 6000 Cre
CRE
Cobas 8000 Cre
Abbott Laboratories, Abbott Park,
Il, USA
Architect C16000 Cre
Siemens, Erlangen, Germany Dimension Vista 1500 ECR
Advia 1650 CRE
Sysmex Europe, Norderstedt,
Germany
Olympus AU2700 Cre
Ortho Clinical Diagnostics (OCD) Inc,
Rochester, NY, USA
Vitros 5600 CRE
Vitros 5,1 FS CRE
AP-K = alkaline picrate kinetic; AP-RB = alkaline picrate rate-blanked; C = compensatethe participant’s laboratory at −20°C. The participants
analyzed each pool in 5-fold on their automated chemis-
try analyzer in routine and within 3 hours after thawing
of the samples. The participants delivered information
on the instrument, reagents and the method applied.
The study included 26 routine methods, representing 13
different types of analyzers from 6 manufacturers cover-
ing all current methodologies. Serum creatinine was
measured either enzymatically (E), liquid or dry or by a
Jaffe method, alkaline picrate kinetic (AP-K) or with an
alkaline picrate rate-blanked method (AP-RB) with com-
pensation (C) or without compensation (NC) (Table 1).
In a dry chemistry assay, the sample is deposited onto a
multi-layered slide and evenly distributes into the slide
that contains all appropriate substrates and other com-
ponents for a reaction. A liquid assay takes place in a li-
quid environment. The AP-RB method was developed to
reduce bilirubin interference. The rate of colour change
in the sample at alkaline pH is used as a correction fac-
tor for the rate observed after the addition of picric acid.
One participant included four of their routine Cobas
6000 (Roche) instruments in the study, another partici-
pant included two Integra 800 (Roche) instruments. The
laboratory working with the LX 20 Clinical System
(Jaffe) and the laboratory working with the Dimension
Vista 1500 (Jaffe) reported their results (in mg/dL) ac-
curate to the nearest tenth, while all the other laborator-
ies reported results accurate to the nearest hundredth.gent No. Method
m (Creatinine) Reagent n = 1 AP-K, NC
m (Creatinine) Reagent n = 1 AP-K, NC
A Creatinine Jaffe method
pensated
n = 2 AP-RB, C
atinine Jaffé Gen.2 compensated,
P2 Creatinine plus vers.2
n = 2 AP-K, C and E liquid
atinine Jaffé Gen.2 compensated,
P2 Creatinine plus vers.2
n = 3 AP-K, C and E liquid
atinine Jaffé Gen.2 compensated,
P2 Creatinine plus vers.2
n = 6 AP-K, C and E liquid
atinine Jaffé Gen.2 compensated n = 2 AP-RB, C
aC n = 2 AP-K, NC
EA, CREA: Dimension Vista creatinine n = 2 E liquid or AP-K, NC
A n = 1 AP-K, NC
atinine Jaffe n = 1 AP-K, NC
A slides n = 1 E dry
A slides n = 2 E dry
d; NC = non-compensated; E = enzymatic.
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To estimate the effect of the variation in Scr determina-
tions on the eGFR, we calculated eGFR values corre-
sponding with the minimum and maximum determined
Scr values of each pool for some specific patient cases.
The first pool (35 μmol/L) corresponded with the average
Scr value of a six year old healthy child with a length of
116.5 cm. There are multiple eGFR equations to calculate
the GFR in children [6,8,15,16]. We used the Schwartz
equation which is nowadays still the most used formula to
calculate the eGFR in the pediatric population [6,8]. Al-
though the minimum and maximum Scr values for this
pool were determined with Jaffe type assays we used the
updated Schwartz formula [eGFR = 0.413 * length (cm)/
Scr (mg/dL)] [8], since the original Schwartz formula [6]
has been validated 30 years ago using Jaffe recipes that are
no longer on the market [17]. For pool 2 to 5, we used the
CKD-EPI equation [eGFR = 141 * min(Scr/κ,1)α * max
(Scr/κ,1)-1.209 * (0.993)Age * (1.018 if female) * (1.159 if
black) where Scr expressed in mg/dL and κ = 0.90 mg/dL
for males and 0.70 mg/dL for females; α = −0.411 for
males and −0.329 for females] to calculate the eGFR for
both an 18 year as well as a 65 year old woman and man
[11]. To convert Scr from the SI-unit (μmol/L) to the con-
ventional unit (mg/dL), the SI-unit must be divided by the
conversion factor 88.4. The corresponding CKD stages
(Grade (G) 1–5) can be found in Table 2.
Statistical analysis
For each instrument, the mean of the 5 measurements
of each pool and the standard deviation (SD) wereTable 2 eGFR calculations and subsequent CKD classification
results obtained for each pool
Pool, μmol/L 1 2
35 70
Min and max Scr, μmol/L 27 53 59
eGFR, ml/min/1.73 m2 child 6y 158 80a,b
CKD stage G1 G2
man 18y 140
CKD stage G1
woman 18y 128
CKD stage G1
man 65 y 101
CKD stage G1
woman 65y 92a,b
CKD stage G1
The updated Schwartz formula was used for eGFR calculation in the 6 year old child w
adults [11] (see Methods section).
(Grade 1) Normal GFR: ≥90 mL/min/1.73 m2, (Grade 2) Mild impairment: 60-89 mL/m
(Grade 3b) Moderate to severe impairment: 30-44 mL/min/1.73 m2, (Grade 4) Severe im
min/1.73 m2. In the absence of kidney damage, Grade 1 and 2 cannot be considered a
aIndicates cases for which eGFR calculated for the minimum and maximum serum c
bIndicates cases for which the calculated CKD stage is different from the CKD stagecalculated. Analytical imprecision (i.e. the degree of
agreement of replicate measurements) of each analyzer
was assessed by calculating the intra-run coefficient of
variation (CVi)(%) (n = 5). Also the bias (B)(%) was cal-
culated as [(measured Scr – ID-GC/MS target value
Scr)/ ID-GC/MS target value Scr]*100. CVi and bias
were compared to the performance specifications for
creatinine as reported in the Ricos-Fraser et al. database
(Additional file 1) [18]. Finally, an error (1.65CVi + B)
was calculated and compared to the Ricos-Fraser total
error (TE) to estimate the leftover budget for the not
known inter-run CV (inter-run experiments not per-
formed). The Ricos-Fraser database is based on the
within- and between subject variation of laboratory
parameters. The database defines the insufficient, min-
imal, desirable and optimal analytical precision, bias and
total error of an analytical assay (eg. for creatinine see
Additional file 1).
Results
Experimental design
The concentrations of the five creatinine serum pools
were chosen carefully. Pool 1 was designed to corres-
pond to the average Scr concentration of a six year old
child (around 35 μmol/L) [15]. Pool 2 was designed to
be in the pathological Scr range for children or within
the normal adult creatinine concentration range (around
70 μmol/L). Pool 3 was targeted just above the upper
reference limit of adult men (around 112 μmol/L) [19],
pool 4 and 5 were set in the higher concentration range
(>177 μmol/L).based on minimum and maximum serum creatinine
3 4 5
112 296 934
80 104 124 274 313 868 990
124 90a,b 73 28 24 7 6
G1 G1 G2 G4 G4 G5 G5
93 68 55a,b 21 18 5 4
G1 G2 G3a G4 G4 G5 G5
89a,b 65a,b 52 20 17 5 4
G2 G2 G3a G4 G4 G5 G5
67 49a,b 39 15 13a,b 4 3
G2 G3a G3b G4 G5 G5 G5
ith a length = 116.5 cm [8]. The CKP-EPI formula was used for eGFR calculations in
in/1.73 m2, (Grade 3a) Mild to moderate impairment: 45-59 mL/min/1.73 m2,
pairment: 15-29 mL/min/1.73 m2 and (Grade 5) End stage renal disease: <15 mL/
s CKD, but Grade 3 is always considered as CKD.
reatinine values classify patients in different CKD stages.
obtained when the target value of the pool is used.
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standard method (ID-GC/MS)
The target values (mean ± SD) (ID-GC/MS) of the
5 pools were 35.0 ± 0.004 μmol/L (pool 1), 69.9 ±
0.003 μmol/L (pool 2), 111.8 ± 0.005 μmol/L (pool 3),
296.1 ± 0.013 μmol/L (pool 4) and 933.5 ± 0.011 μmol/L
(pool 5).
Assessment of commutability
To obtain a serum pool, consecutive leftovers of patient
samples were added to the already frozen bulk. The in-
fluence of freezing and later thawing of the thus ob-
tained pool on commutability was tested on a Cobas
6000 (Roche), as described in the method section. The
mean ± SD of the creatinine was 46.3 ± 0.7 μmol/L for
the liquid pool and 45.8 ± 0.9 μmol/L for the defrosted
pool. The true mean difference between the pools is
0.5 μmol/L with a SD of 0.8 μmol/L and is lying between
the predefined equivalence limits of −2.0 and 2.0 μmol/L.
The effect of the freeze-thaw cycle is therefore not consid-
ered affecting commutability.
Serum creatinine measurements: CVi, bias and error
calculations
The Ricos-Fraser criteria were used for assessment
of the performance characteristics of the creatinineFigure 1 Intra-run variation of the individual analyzers for each pool
presented. Solid horizontal line: minimal (<4.5%). Dashed horizontal line: de
reported precision (to the nearest tenth).assays. These criteria are dependent on the within-
subject (6.0%) and between-subject (14.7%) variation of
creatinine and are commonly used in laboratory practice
to subdivide the quality of the performance of an assay
into four categories: optimal, desirable, minimal and in-
sufficient (Additional file 1). A good analytical assay
should have a low imprecision (CVi) compared with the
within-subject biological variation and a low bias (B)
compared to the target or true value.
Intra-laboratory variation CVi
In Figure 1 the CVi of the individual analyzers for each
pool according to the type of creatinine assay is shown.
81% (21/26) of the analyzer results from pool 1 and 92%
(24/26) of the analyzer results from pool 2 met the min-
imal analytical variation criterion of 4.5% (black line).
For pool 3 to 5, >95% of all test results were within
the minimal specification criterion. Only Jaffe and/or
compensated Jaffe assays did not met the minimal
specifications for pool 1 and/or 2 (lower creatinine
concentrations). All enzymatic assays were within the
minimal specifications.
Bias
In Figure 2 the bias of the individual analyzers for each
pool according to the creatinine assay type is presented.according to the type of creatinine assay. Ricos-Fraser goals are
sirable (<3.0%). LX20 Clinical System shows no intra-run CV within the
Figure 2 Bias of the individual analyzers for each pool according to the type of creatinine assay. Ricos-Fraser goals are presented. Solid
horizontal line: minimal (<5.9%). Dashed horizontal line: desirable (<4.0%).
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1) has the largest bias for almost all analyzers. For this
pool, 62% (16/26) of the analyzers failed to reach the
minimal bias specification of 5.9% (black line). Some
Jaffe methods (Dimension Vista 1500 (Siemens) and the
two Architect C16000 analyzers (Abbott)) gave very
large biases (up to 30%). Also all dry chemistry analyzers
(n = 3) (Ortho Clinical Diagnostics Inc.) showed un-
acceptable positive biases for pool 1 according to Ricos-
Fraser. For pool 2, 77% (20/26) of all methods met the
minimal bias specifications (<5.9%), but only 50% (13/
26) met the desirable bias criterion (<4.0%). For pool 3–
5 which are in the adult pathological range, respectively
100%, 88% and 100% of the analyzers met the minimal
bias specification. The liquid enzymatic assays (n = 8)
have the best score over the whole concentration range,
although for pool 1 they all showed negative biases.
Moreover, 5 out of 8 of these negative biases are
unacceptable.Error calculations (CVi and bias)
An error based on CVi and bias (inter-run CV not taken
into account) was calculated and compared with the
Ricos-Fraser TE (Figure 3). Inter-run experiments were
not performed so the actual TEs would presumably be
higher than these ‘intermediate’ calculated errors. The
calculated errors were compared with the minimal
(<13.3%, solid line), desirable (<8.9%, dashed line) and op-
timal (<4.5%, dotted line) Ricos-Fraser TE categories.
Concerning pool 1, the acceptable error (13.3%) was
already exceeded for 5 out of 7 Jaffe, for 3 out of 7 com-
pensated Jaffe and for all three dry chemistry analyzers.
Extreme errors were calculated for the two Architect
C1600 analyzers (Jaffe) (29.2% and 31.7%) and for the Di-
mension Vista 1500 (Jaffe) (50.7%). For pool 2 the Dimen-
sion Vista 1500 (Jaffe) and one Integra 800 (compensated
Jaffe) showed insufficient results when compared with the
Ricos-Fraser TE criteria. The error calculations for pool
3–5 all fell within the TE budget of Ricos-Fraser.
Figure 3 Error calculations based on CVi and bias. Ricos-Fraser total error goals are presented. Solid horizontal line: minimal (<13.3%). Dashed
horizontal line: desirable (<8.9%). Dotted horizontal line: optimal (<4.5%).
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In Table 2 the minimum and maximum Scr obtained
from the individual measurements of each pool in the
study can be found. The calculated eGFR values corre-
sponding with these Scr values are also presented. De-
pending on the Scr assay, a six year old healthy child
(length = 116.5 cm) with a Scr value of 35 μmol/L (pool
1) or an 18 year old man with a Scr of 112 μmol/L (pool
3) could be classified in CKD stage G1 or G2. Also a
65 year old woman or man with a Scr concentration of
70 μmol/L (pool 2) could be classified in CKD stage G1
or G2, while a woman of 18 or a man of 65 years with a
Scr of 112 μmol/L (pool 3) were classified in stage G2 or
G3. A 65 year old women with a Scr value of 112 μmol/L
(pool 3) could be classified in stage G3a or G3b. All cases
of pool 4 (296 μmol/L), except for the woman aged
65y (G5), corresponds with CKD stage G4. Pool 5
(934 μmol/L) corresponds with CKD stage G5. Overall,
in 8/17 cases (47%) a different CKD stage was assigned.In the absence of kidney damage (albuminuria, urine
sediment abnormalities, electrolyte and other abnor-
malities due to tubular disorders, abnormalities de-
tected by histology, structural abnormalities detected
by imaging, history of kidney transplantation) Grade 1
and Grade 2 cannot be considered as CKD, but Grade 3
is always considered as CKD, as only the GFR criterion
is then relevant for the CKD diagnosis.
Discussion
In this study we investigated the variability in Scr mea-
surements (CVi, bias and TE) in clinical laboratories in
Flanders. The results were grouped according to meth-
odology to reflect how results can vary if patients are
tested in different laboratories using various assays.
Unacceptable CVi, bias and TE were particularly en-
countered at low creatinine concentrations. At higher
creatinine concentrations, CVi, bias and TE tended to
decrease (Figures 1 and 2). Overall we can say that the
Hoste et al. BMC Nephrology  (2015) 16:21 Page 8 of 9enzymatic methods, especially the liquid ones, are per-
forming much better than the Jaffe type assays.
Two participants (LX 20 Clinical System (Jaffe) and
Dimension Vista 1500 (Jaffe)) reported results (in mg/
dL) which were only accurate to the nearest tenth.
Their results should therefore be interpreted with cau-
tion. We recommend to report Scr accurate to the
nearest hundredth.
The bias in the Jaffe methods is likely due to the non-
creatinine chromogens interferences. The compensation
made for the mean pseudo-chromogens in the compen-
sated Jaffe assay is an oversimplification because of the
variability of these chromogens between different pa-
tients and patient groups. Dry chemistry analyzers
showed unacceptable positive biases for the lowest con-
centration pool. The marked differences with the enzym-
atic liquid assays may suggest that the positive bias in
the dry chemistry method could be due to differences in
calibration. After Delanghe’s work in 2008 [20] Ortho
Clinical Diagnostics Inc. recalibrated its assay resulting
in better outcomes in a concentration range >77 μmol/L
[5]. According to our results, all dry chemistry assays
still gave too large biases for pool 1 (35 μmol/L); for pool
2 (70 μmol/L) the biases are within the minimal bias
specification criterion.
The Flanders experience is in line with a Dutch and
French multicentric evaluation performed in 2012 and
2013: the (compensated) Jaffe creatinine methods did
not reach the desirable specifications of NKDEP at nor-
mal levels of creatinine [3,21]. The two groups also
showed that enzymatic methods on the other hand have
an excellent traceability to the ID-GC/MS reference
method for creatinine [5] except for the dry chemistry
methods. In this project, the calculated errors of the
liquid enzymatic assays were within the minimal TE cri-
terion of 13.3% for all five studied creatinine concentra-
tions. We demonstrated that attention should be paid
when dry chemistry methods are used to determine low
Scr values. Pool 1 (35 μmol/L) largely exceeded the min-
imal TE. This has major consequences for the assess-
ment of renal function and CKD staging (which are
mostly estimated by creatinine-based equations) in the
pediatric population. Also for other patients with low
Scr values (like anorectic or cancer patients or the eld-
erly) and even for the healthy population, one should be
aware of the shortcomings of the creatinine assay used.
One could argue that the Ricos-Fraser approach is not
applicable at very low substance concentrations. The lit-
erature provides little information on the performance
characteristics of creatinine when using this parameter
as a diagnostic test in neonates and children or in adult
patients with low serum creatinine. However, based on
the pediatric within-subject variation of 6.4% and the
pediatric between-subject variation of 20.1% publishedby Andersen et al. [22], the minimal specifications are
4.8% for CVi, 7.9% for bias and 15.8% for TE (Ricos-Fra-
ser approach). These minimal specifications are very
similar to those published by Ricos et al. [18] (Additional
file 1). Information about performance specifications
based on clinical needs is also scarce. A paper by
Schwartz et al. [23] considers an increase of Scr from
26.5 to 35.4 μmol/L, or a change of 33% of major clinical
significance in children. This implies that the TE should
be ≤20-30% in the pediatric creatinine range. According
to KDIGO (Kidney Disease–Improving Global Out-
comes) a change in GFR by 5 mL/min/1.73 m2 is consid-
ered as clinically relevant [24]. For a person with a GFR
of 100 mL/min/1.73 m2 this corresponds with a TE of
5%. Based on the biological variability of the GFR and
based on our experience, a change in GFR of at least
10% is clinically relevant. When using the updated
Schwartz equation [8] for calculating the eGFR in the
pediatric population, an analytical bias of 5% or a TE of
10% on the Scr concentration leads to the same bias or
TE on the calculated eGFR value. Based on the above
mentioned arguments, we also used the criteria of
Ricos-Fraser for pool 1 (35 μmol/L) with a target value
in the pediatric concentration range.
Our study has several strengths. We studied 26 routine
instrumental methods, representing 13 different types of
analyzers from 6 different manufacturers which deliv-
ered test results of five pools covering a wide creatinine
concentration range from 35 to 934 μmol/L. Moreover,
fresh frozen serum samples were used instead of non-
commutable lyophilized control materials. However, only
three labs working with Vitros instruments and five dif-
ferent labs working with enzymatic liquid assays were in-
volved in the study.
Our data illustrated that the minimum and maximum
Scr values determined for the same pool in different labs
with various assays could lead to a large spread of calcu-
lated eGFR values (Table 2) especially in the lower Scr
concentration range (pool 1–3). The eGFR values calcu-
lated with the reported Scr values might even classify
patients in other CKD stages.
Conclusions
Overall, we can conclude that although most assays
claim to be traceable to ID-GC/MS, large inter-assay dif-
ferences still exist. The inaccuracy in the lower concen-
tration range is of particular concern and may lead to
clinical misinterpretation especially in children and in
patients with muscle wasting and consequently low cre-
atinine values like in anorectic or cancer patients, or in
the elderly. Enzymatic assays, especially the liquid ones,
lead to less variability in Scr measurements than Jaffe
type methods. We therefore advocate a more general use
of the enzymatic creatinine assays, but nevertheless
Hoste et al. BMC Nephrology  (2015) 16:21 Page 9 of 9attention should still be paid in the lower Scr concentra-
tion range. Further efforts should be made to improve
the calibration of commercialized creatinine assays so
that the CVi, bias and TE are kept within the minimal
criteria of Ricos-Fraser.
Additional file
Additional file 1: Imprecision, bias and total error criteria according
to Ricos-Fraser. CVw: within subject biological variation = 6.0% and
CVb: between subject variation = 14.7% [18].
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